Charles Schwab Investment Management Inc. Purchases 2,270 Shares of AngioDynamics, Inc. (NASDAQ:ANGO)

Charles Schwab Investment Management Inc. lifted its position in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 0.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 329,090 shares of the medical instruments supplier’s stock after purchasing an additional 2,270 shares during the period. Charles Schwab Investment Management Inc. owned 0.81% of AngioDynamics worth $3,014,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in ANGO. FMR LLC boosted its position in AngioDynamics by 105.0% in the third quarter. FMR LLC now owns 52,779 shares of the medical instruments supplier’s stock worth $411,000 after purchasing an additional 27,031 shares during the last quarter. BNP Paribas Financial Markets boosted its holdings in shares of AngioDynamics by 110.4% in the 3rd quarter. BNP Paribas Financial Markets now owns 159,391 shares of the medical instruments supplier’s stock worth $1,240,000 after buying an additional 83,622 shares during the last quarter. Walleye Capital LLC purchased a new position in shares of AngioDynamics in the 3rd quarter worth about $546,000. Quarry LP grew its position in AngioDynamics by 40.9% during the third quarter. Quarry LP now owns 8,518 shares of the medical instruments supplier’s stock valued at $66,000 after buying an additional 2,471 shares during the period. Finally, Systematic Financial Management LP increased its holdings in AngioDynamics by 14.3% during the third quarter. Systematic Financial Management LP now owns 2,410,346 shares of the medical instruments supplier’s stock worth $18,752,000 after buying an additional 300,785 shares during the last quarter. 89.43% of the stock is owned by institutional investors.

Insider Activity

In related news, SVP Warren Nighan, Jr. sold 4,060 shares of the stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $12.31, for a total transaction of $49,978.60. Following the sale, the senior vice president now owns 41,817 shares of the company’s stock, valued at approximately $514,767.27. This represents a 8.85 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 5.40% of the stock is owned by company insiders.

Analysts Set New Price Targets

Separately, HC Wainwright increased their target price on shares of AngioDynamics from $14.00 to $15.00 and gave the company a “buy” rating in a research report on Friday, January 10th.

AngioDynamics Stock Performance

Shares of ANGO opened at $9.83 on Friday. The firm has a market cap of $397.78 million, a P/E ratio of -1.75 and a beta of 0.56. AngioDynamics, Inc. has a fifty-two week low of $5.47 and a fifty-two week high of $13.50. The business has a 50-day moving average of $10.47 and a 200 day moving average of $8.77.

AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings results on Wednesday, January 8th. The medical instruments supplier reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.07. The company had revenue of $72.90 million for the quarter, compared to analyst estimates of $70.93 million. AngioDynamics had a negative net margin of 79.38% and a negative return on equity of 7.26%. The company’s quarterly revenue was down .1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.05) earnings per share. As a group, research analysts predict that AngioDynamics, Inc. will post -0.37 earnings per share for the current fiscal year.

AngioDynamics Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.